Cognizant announced its tech deal with Alnylam Pharmaceuticals marking a shift in Alnylam’s approach to IT and business operations.
Cognizant, as an IT Managed Services provider, will manage Alnylam’s infrastructure, cloud, security, platforms, applications, and data analytics.
Leveraging its expertise in the life sciences sector, Cognizant will use advanced managed services frameworks and tools to streamline Alnylam’s operations, improve automation, and reduce operational efforts. This partnership will enhance transparency in decision-making and accountability, setting a solid foundation for Alnylam’s scalability and business growth.
The collaboration underscores Cognizant’s commitment to driving Alnylam’s mission of delivering life-changing RNA interference (RNAi) therapies for patients with rare and prevalent diseases. Through this alliance, Cognizant will bring its proficiency in deploying technology solutions for top pharmaceutical companies, enhancing Alnylam’s ability to meet its goals faster.
By integrating AI-driven insights, advanced data analytics, and managed services, Cognizant will enable Alnylam to better address the unique challenges of the biopharmaceutical industry, accelerate its business outcomes, and improve customer experiences.
